Genelux (NASDAQ:GNLX) Issues Earnings Results, Misses Expectations By $0.02 EPS

Genelux (NASDAQ:GNLX) issued its quarterly earnings data on Thursday. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02), FiscalAI reports.

Genelux Price Performance

NASDAQ GNLX traded up $0.28 during trading on Friday, hitting $3.11. The company’s stock had a trading volume of 368,403 shares, compared to its average volume of 151,441. The company has a market cap of $139.45 million, a PE ratio of -3.66 and a beta of 0.51. The business’s 50 day simple moving average is $2.64 and its 200-day simple moving average is $3.75. Genelux has a fifty-two week low of $2.29 and a fifty-two week high of $8.53.

Insiders Place Their Bets

In other Genelux news, Director John Thomas sold 10,000 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $2.90, for a total value of $29,000.00. Following the completion of the sale, the director owned 482,784 shares of the company’s stock, valued at approximately $1,400,073.60. This trade represents a 2.03% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 8.80% of the company’s stock.

Institutional Investors Weigh In On Genelux

Institutional investors have recently added to or reduced their stakes in the business. ExodusPoint Capital Management LP acquired a new stake in Genelux in the fourth quarter worth about $238,000. OMERS ADMINISTRATION Corp acquired a new stake in Genelux in the fourth quarter worth about $239,000. Hudson Bay Capital Management LP acquired a new stake in Genelux in the fourth quarter worth about $165,000. Susquehanna International Group LLP boosted its holdings in Genelux by 140.3% in the third quarter. Susquehanna International Group LLP now owns 52,383 shares of the company’s stock worth $220,000 after acquiring an additional 30,583 shares in the last quarter. Finally, Creative Planning boosted its holdings in Genelux by 4.7% in the third quarter. Creative Planning now owns 46,108 shares of the company’s stock worth $194,000 after acquiring an additional 2,084 shares in the last quarter. Institutional investors and hedge funds own 37.33% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Wall Street Zen downgraded Genelux from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Benchmark dropped their price objective on Genelux from $23.00 to $20.00 and set a “speculative buy” rating on the stock in a research report on Friday, March 20th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Genelux in a research report on Tuesday, April 21st. Three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $18.00.

Genelux Company Profile

Genelux Corporation (NASDAQ:GNLX) is a clinical-stage biotechnology company focused on the development of oncolytic virus immunotherapies. Built on a proprietary vaccinia virus platform, the company’s programs are designed to selectively infect and destroy cancer cells while stimulating a systemic immune response. Genelux’s lead candidate, pexastimogene devacirepvec (GL-ONC1), is being evaluated in multiple indications, including peritoneal malignancies and head and neck cancers, where it is administered either intraperitoneally or systemically depending on the trial design.

Genelux’s pipeline leverages its experience with the GL-ONC1 construct to explore combination strategies with chemotherapy and immuno-oncology agents.